Edwards DR, Denhardt DT: A study of mitochondrial and nuclear transcription with cloned cDNA probes. Changes in the relative abundance of mitochondrial transcripts after stimulation of quiescent mouse fibroblasts. Exp Cell Res. 1985, 157: 127-143. 10.1016/0014-4827(85)90157-0.
Lim YC, Desta Z, Flockhart DA, Skaar TC: Endoxifen has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005, 55: 471-8. 10.1007/s00280-004-0926-7.
Ullmannova V, Haskovec C: The use of housekeeping genes (HKG) as an internal control in the detection of gene expression by quantitative real time RT-PCR. Folia Biol. 2003, 49: 211-6.
Oliveira JG, Prados RZ, Guedes AC, Ferreira PC, Kroon EG: The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase is inappropriate as internal control in comparative studies between skin tissue and cultured skin fibroblasts using Northern blot analysis. Arch Dermatol Res. 1999, 291: 659-661. 10.1007/s004030050471.
Bustin SA: Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000, 25: 169-193. 10.1677/jme.0.0250169.
Barroso I, Benito B, Garci-Jimenez C, Hernandez A, Obregon MJ, Santisteban P: Norepinephrine, tri-iodothyronine and insulin upregulate glyceraldehyde-3-phosphate dehydrogenase mRNA during Brown adipocyte differentiation. Eur J Endocrinol. 1999, 141: 169-179. 10.1530/eje.0.1410169.
Desprez PY, Poujol D, Saez S: Glyceraldehyde-3-phosphate dehydrogenase gene expression in two malignant human mammary epithelial cell lines: BT-20 and MCF-7 regulation of gene expression by 1,25 dihydroxyvitamin D3 (1,25-(OH)2D3). Cancer Lett. 1992, 64: 219-244. 10.1016/0304-3835(92)90046-X.
Revillion F, Pawlowski V, Hornez L, Peyrat JP: Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Eur J Cancer. 2000, 36: 1038-1042. 10.1016/S0959-8049(00)00051-4.
Chang TJ, Juan CC, Yin PH, Chi CW, Tsay HJ: Up-regulation of beta-actin, cyclophilin and GAPDH in N1S1 rat hepatoma. Oncol Rep. 1998, 5: 469-471.
Bhatia P, Taylor WR, Greenberg AH, Wright JA: Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for northern blot analysis of cell lines of varying malignant potential. Anal Biochem. 1994, 216: 223-226. 10.1006/abio.1994.1028.
Ripple MO, Wilding G: Alteration of glyceraldehyde-3-phosphate dehydrogenase activity and messenger RNA content by androgen in human prostate carcinoma cells. Cancer Res. 1995, 55: 4234-4236.
Varghese S, Canalis E: Alendronate stimulates Collagenase 3 expression in osteoblasts by posttranscriptional mechanisms. J Bone Miner Res. 2000, 15: 2345-2351.
Dalle Carbonare L, Valenti MT, Azzarello G, Balducci E, Crepaldi G, Realdi G, Vinante O, Giannini S: Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. Mol Cell Endocrinol. 2005, 240: 23-31. 10.1016/j.mce.2005.03.018.
Fleish H: Experimental basis for the use of bisphosphonates in Paget's disease of bone. Clin Othop. 1987, 217: 72-78.
Flanagan AM, Chambers TJ: Inhibition of bone resorption by bisphosphonate, osteoclast, and bone. Calcif Tissue Int. 1991, 49: 407-415.
Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonates treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001, 61: 2602-2608.
Boisser S, Magnetto S, Frapport L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized bone extracellular matrices. Cancer Res. 1997, 57: 3890-3894.
Brown JE, Neville-Webbe H, Coleman RE: The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer. 2004, 11: 207-24. 10.1677/erc.0.0110207.
Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol. 1997, 98: 665-72. 10.1046/j.1365-2141.1997.2713086.x.
Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR, Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer. 2003, 88: 1971-1978. 10.1038/sj.bjc.6600986.
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanism of action of bisphosphonates. Cancer. 2000, 88: 2961-297. 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L.
Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC: Bisphosphonates Pamidronate and Zoledronic acid Stimulates osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002, 291: 680-686. 10.1006/bbrc.2002.6510.
Green JR: Bisphosphonates: preclinical review. Oncologist. 2004, 9: 3-13. 10.1634/theoncologist.9-90004-3.
Fromigue O, Lagneaux L, Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000, 15: 2211-2221.
Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res. 1996, 6: 986-994.
Chaplet M, Detry C, Deroanne C, Fisher LW, Castronovo V, Bellahcene A: Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochemical J. 2004, 384: 591-598. 10.1042/BJ20040380.
Takagi K, Takagi M, Kanangat S, Warrington KJ, Shigemitsu H, Postlethwaite AE: Modulation of TNF-alpha gene expression by IFN-gamma and Pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol. 2005, 174: 1801-1810.
Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AB: The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activing TNF-alpha converting enzyme (TACE). J Bone Miner Res. 2004, 19: 147-154.
Myoung H, Park JY, Choung PH: Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. J Periodontal Res. 2001, 36: 244-251. 10.1034/j.1600-0765.2001.036004244.x.
Kim YH, Kim GS, Jeong-Hwa B: Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med. 2002, 34: 145-151.
Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K: Nitrogen-containing bisphosphonates, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun. 2005, 328: 91-97. 10.1016/j.bbrc.2004.12.145.
Gomez-Garcia L, Esbrit P, Carreno L, Sabando P, Garcia-Flores M, Martinez ME: Alendronate interacts with the inhibitory effect of 1,25 (OH)2D3) on Parathyroid Hormone-Related Protein Expression in Human osteoblastic cells. J Bone Miner Res. 2003, 18: 78-87.
Yasui T, Fujita K, Sasaki S, Iguchi M, Hirota S, Nomura S, Azuma Y, Ohta T, Kohri K: Alendronate inhibits osteopontin expression enhanced by parathyroid hormone-related peptide (PTHrp) in the rat kidney. Urol Res. 1998, 26: 355-360. 10.1007/s002400050069.
Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I: Sequence and schedule-Dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 2005, 113: 364-371. 10.1002/ijc.20602.
Van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE: Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 2003, 33: 805-11. 10.1016/j.bone.2003.07.007.
Xing C, LaPorte JR, Barbay JK, Myers AG: Identification of GAPDH as a protein target of the saframycin antiproliferative agents. Proc Natl Acad Sci USA. 2004, 101: 5862-5866. 10.1073/pnas.0307476101.
Sirover MA: New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta. 1999, 1432: 159-184.
Krynetski EY, Krynetskaia NF, Gallo AE, Murti KG, Evans WE: A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol. 2001, 59: 367-74.
Zheng L, Roeder RG, Luo Y: S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell. 2003, 114: 255-266. 10.1016/S0092-8674(03)00552-X.
Appelskog IB, Ammerpohl O, Svechnikova IG, Lui WO, Almqvist PM, Ekstrom TJ: Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA Expression in glioma cells. Int J Oncol. 2004, 24: 1419-25.
Tatton WG, Chalmers-Redman RM, Elstner M, Leesch W, Jagodzinski FB, Stupak DP, Sugrue MM, Tatton NA: Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signalling. J Neural Transm. 2000, 60: 77-100.